EMA — authorised 12 September 2021
- Marketing authorisation holder: Janssen-Cilag International N.V.
- Status: approved
🇪🇺 Rybrevant in European Union
EMA authorised Rybrevant on 12 September 2021
Marketing authorisation
Rybrevant in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Oncology approved in European Union
Frequently asked questions
Is Rybrevant approved in European Union?
Yes. EMA authorised it on 12 September 2021.
Who is the marketing authorisation holder for Rybrevant in European Union?
Janssen-Cilag International N.V. holds the EU marketing authorisation.